Translational Research of Finasteride and Selenium Prevention of Prostate Cancer

描述（由申请人提供）：该计划项目的目标是开发一种新的机制驱动的前列腺癌预防策略。该方法是基于在两个不同的步骤同时抑制雄激素信号转导，通过使用非那雄胺抑制二氢睾酮的形成和硒减少雄激素受体（AR）的表达。该计划是建立在沿着一个板凳到床边的范例，并由三个高度集成的项目。项目1是描述在控制前列腺癌细胞的克隆性扩增中，非那肽和硒如何协同作用来调节某些分子事件。特别强调的是放在功能分析的关键目标和途径，负责诱导细胞凋亡后的治疗与finalide/硒。由于脉管系统的异常，在增殖的癌细胞集落中经常看到微环境缺氧。众所周知，缺氧作为生存的选择性压力产生多种分子变化。最近有证据表明，缺氧促进AR激活和雄激素反应基因的转录。上述过程是由一种称为过氧化物氧还蛋白-1或Prx 1的氧化还原调节蛋白介导的。Prx 1在前列腺上皮内瘤变和前列腺癌细胞中优先升高。项目2是研究缺氧/Prxl刺激AR信号传导的机制，并评估Prxl在修饰非那肽/硒的癌症控制功效中的作用。项目1和2的发现对于项目3的临床试验结果的解释至关重要。提出了一项短期干预试验，以验证finalide/硒对从前列腺切除术前患者获得的前列腺组织样品中雄激素靶基因表达和细胞凋亡诱导的影响。该试验的第二个目的是确定高水平的Prx 1是否会降低对芬氟拉明/硒干预的敏感性。每年，在美国大约有23万例新的前列腺癌病例被诊断出来，大约3万名男性将死于这种疾病。作为一个公共卫生问题，前列腺癌产生巨大的医疗保健和人类痛苦的成本。阻断小体积、低级别肿瘤的进展越来越被认为是前列腺癌控制的一个重要方面。我们的目标是找到一种在早期阶段管理这种疾病的方法，以防止它成为临床相关的。

DESCRIPTION (provided by applicant): The objective of the program project is to develop a novel mechanism-driven strategy for prostate cancer prevention. The approach is based on suppressing androgen signal transduction at two different steps simultaneously by using finasteride to inhibit the formation of dihydrotestosterone and selenium to reduce androgen receptor (AR) expression. The program is built along a bench-to-bedside paradigm and consists of three highly integrated projects. Project 1 is to delineate how finasteride and selenium work cooperatively to modulate certain molecular events in controlling the clonal expansion of prostate cancer cells. Special emphasis is placed on the functional analysis of key targets and pathways responsible for the induction of apoptosis following treatment with finasteride/selenium. Microenvironmental hypoxia is frequently seen in a colony of proliferating cancer cells due to abnormalities of the vasculature. It is well known that hypoxia produces a variety of molecular changes as a selective pressure for survival. There is recent evidence suggesting that hypoxia facilitates AR activation and the transcription of androgen-responsive genes. The above process is mediated by a redox-regulating protein called peroxiredoxin-1, or Prx1. Prx1 is preferentially elevated in prostatic intraepithelial neoplasia and prostate cancer cells. Project 2 is to investigate the mechanism of hypoxia/Prxl stimulation of AR signaling and to assess the role of Prx1 in modifying the cancer control efficacy of finasteride/selenium. The findings of Projects 1 and 2 are critical to the interpretation of the clinical trial results of Project 3. A short-term intervention trial is proposed to verify the effect of finasteride/selenium on androgen target gene expression and apoptosis induction in prostate tissue samples obtained from pre-prostatectomy patients. A second objective of the trial is to determine whether a high level of Prx1 diminishes the sensitivity to finasteride/selenium intervention. Every year, approximately 230,000 new cases of prostate cancer are diagnosed in the US, and some 30,000 men will die of this disease. As a public health problem, prostate cancer engenders huge medical care and human suffering costs. Blocking the progression of small volume, low-grade neoplasia is increasingly being recognized as an important aspect of prostate cancer control. Our goal is to find a way of managing the disease at an early stage in order to prevent it from becoming clinical relevant.